In diabetic neuropathy, which drug classes have the strongest evidence for initial therapy?

• A. Opioids and NSAIDs
• B. SNRIs (duloxetine) and anticonvulsants (gabapentin, pregabalin)
• C. SSRIs
• D. Beta-blockers

Answer: (B)

Neuropathic pain from diabetic neuropathy responds best when treatment targets the abnormal pain signaling in the nervous system. The strongest evidence for starting pharmacologic therapy comes from SNRI antidepressants like duloxetine and anticonvulsants such as gabapentin and pregabalin. Duloxetine boosts descending pain inhibition by increasing serotonin and norepinephrine in the spinal cord, which dampens pain transmission. Gabapentinoids reduce excitatory neurotransmitter release by binding to the alpha-2-delta subunit of voltage-gated calcium channels, leading to lower pain signaling. Together, they have been consistently shown in trials to relieve pain and improve function in diabetic neuropathy.

In contrast, opioids and NSAIDs have less robust evidence for treating this type of neuropathic pain and carry risks with long-term use. SSRIs generally show weaker or inconsistent benefits for neuropathic pain, and beta-blockers have no role in managing neuropathic pain. So the best-supported initial choices are SNRI antidepressants and anticonvulsants.